Pharmacological Prophylaxis of Post- Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

• Status: Unknown status
• Trial end date: 2018-12-15
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of post-ERCP pancreatitis, using pharmacologic agents with different mechanisms of action (NSAIDs and/or acetylcysteine) in three different regimens.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Grigore T. Popa University of Medicine and Pharmacy
• Treatments: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Indomethacin; N-monoacetylcystine

Criteria

Inclusion Criteria:

• age 18 years and older

• diagnosis of choledocholithiasis

• indication for ERCP procedures

• willingness to participate in the study

• the ability to sign the informed consent

Exclusion Criteria:

• presence of acute pancreatitis or other inflammatory diseases at admission

• pregnancy

• contraindication for NSAID administration

• recent episode of upper digestive bleeding (less than one month)

• hypersensibility to antioxidants hypersensibility to antioxidants

• the necessity of a prophylactic pancreatic stent insertion

• patients' disapproval to take part in the study